Authors: Chi Ying, Yang Liu DOI: 10.3760/cma.j.cn115989-20211020-00571 Published 2021-11-10 Cite asChin J Exp Ophthalmol, 2021, 39(11): 929-932. Abstract [View PDF] [Read Full Text] Adalimumab, one of the tumor necrosis factor-α (TNF-α) inhibitors, has been approved as a therapeutic drug for non-infectious intermediate, posterior and pan-uveitis […]